Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> 5-Ph-IAA [168649-23-8]

5-Ph-IAA [168649-23-8]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-134653-5mg

Size : 5mg

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

Beschreibung

5-Ph-IAA is a derivative of IAA. 5-Ph-IAA, a ligand, establishes the auxin-inducible degron 2 (AID2) system together with an OsTIR1 (F74G) mutant. AID2 induces rapid and efficient depletion of mAID-fused proteins to study protein function in living cells, causing tumor suppression[1].

In Vitro

5-Ph-IAA (1 μM; 6 hours) leads to DHC1-mAC degradation in HCT116 cells constitutively expressing OsTIR1(F74G), which means the AID2 system better than the original AID system in generating conditional mutant cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5-Ph-IAA Related Antibodies

Western Blot Analysis[1]

Cell Line: HCT116 cells
Concentration: 1 µM
Incubation Time: 6 hours
Result: Depleted DHC1-mAC efficiently in HCT116 cells constitutively expressing OsTIR1(F74G).
In Vivo

5-Ph-IAA (0-10 mg/kg; intraperitoneally injection; every day; 7 days), used for the AID2 system, is sufficient to deplete mAID-BRD4 and TOP2A-mAC, leading to tumour suppression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/c-nu female mice (7 weeks old; 16–20 g ) bearing mAID-BRD4 and TOP2A-mAC xenograft tumours cells[1]
Dosage: 0 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg
Administration: Intraperitoneally injection; every day; 7 days
Result: Displayed significant tumour suppression of mAID-BRD4 xenografts and TOP2A-mAC xenografts.
Molekulargewicht

251.28

Formel

C16H13NO2
CAS. Nr.
Appearance

Solid

Color

White to light yellow

SMILES

O=C(O)CC1=CNC2=C1C=C(C3=CC=CC=C3)C=C2
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Lösungsmittel & Löslichkeit
In Vitro: 

DMSO : 100 mg/mL (397.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.9796 mL 19.8981 mL 39.7962 mL
5 mM 0.7959 mL 3.9796 mL 7.9592 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 1 mg/mL (3.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Reinheit & Dokumentation
Verweise

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
HY-13520-10mg
Nocodazole [31430-18-9]
 10mg